Tirzepatide (LY3298176) is a novel dual GIP and GLP-1 receptor agonist developed for weight management and type 2 diabetes treatment. This investigational peptide demonstrates superior efficacy in clinical trials compared to single-receptor agonists.
As a leading supplier, we offer tirzepatide at competitive prices for research purposes only. Our products undergo rigorous quality control to ensure consistent purity and performance in scientific studies.
The mechanism of action involves simultaneous activation of both GIP and GLP-1 receptors, which enhances insulin secretion, reduces glucagon production, slows gastric emptying, and promotes satiety. This multi-target approach makes tirzepatide particularly effective for metabolic research.
Our tirzepatide prices reflect direct factory sourcing without middleman markups. We provide flexible ordering options from small research quantities to bulk pharmaceutical supplies, all manufactured under strict GMP conditions.
For researchers requiring consistent quality at competitive tirzepatide prices, our production facilities maintain complete documentation including COA, HPLC, and MS analysis for every batch. Custom concentrations and formulations are available for specialized research needs.
Note: This product is for research use only. Not for human consumption. Proper handling procedures should be followed by qualified researchers.